/LPTX
LPTX Stock - Leap Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$1.09+16.57%
+$0.15 (+16.57%) • Dec 19
90
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+404.6%upside
Target: $5.50
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for LPTX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.08 – $1.10
TARGET (TP)$5.50
STOP LOSS$1.00
RISK/REWARD1:49.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.09
52W High$3.58
52W Low$0.22
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | $1.50M | $10.05M |
| Gross Profit | N/A | $-427,000 | N/A | $1.50M | $5.12M |
| Gross Margin | N/A | N/A | N/A | 100.0% | 50.9% |
| Operating Income | $-70,057,000 | $-87,041,000 | $-56,763,000 | $-41,426,000 | $-3,446,000 |
| Net Income | $-67,555,000 | $-81,414,000 | $-54,596,000 | $-40,587,000 | $-3,387,000 |
| Net Margin | N/A | N/A | N/A | -2705.8% | -33.7% |
| EPS | $-1.81 | $-3.98 | $-4.82 | $-4.73 | $-4.64 |
Company Overview
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
1
33%
Hold / Neutral
2
67%
Sell / Underperform
0%
Analyst Consensus🔴 Bearish
1 Bullish2 Neutral/Bearish
Price Targets
$5
Average Target
↑ 324.3% Upside
Now
$1
Low
$5
Average
$8
High
Based on 2 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| January 29th 2025 | H.C. Wainwright | Downgrade | Neutral | - |
| January 29th 2025 | Robert W. Baird | Downgrade | Neutral | $1.25← $9 |
| June 28th 2024 | Rodman & Renshaw | Initiation | Buy | $8 |
Earnings History & Surprises
LPTXBeat Rate
53%
Last 19 quarters
Avg Surprise
-15.8%
EPS vs Estimate
Beats / Misses
10/9
Last 12 quarters
Latest EPS
$-0.08
Q4 2025
EPS Surprise History
Q1 24
+17.9%
$-0.46vs$-0.56
Q2 24
+10.5%
$-0.51vs$-0.57
Q3 24
-23.8%
$-0.52vs$-0.42
Q4 24
+4.3%
$-0.44vs$-0.46
Q1 25
+5.1%
$-0.37vs$-0.39
Q2 25
+2.6%
$-0.37vs$-0.38
Q3 25
-37.9%
$-0.40vs$-0.29
Q4 25
+66.7%
$-0.08vs$-0.24
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 25, 2026 | $-0.20 | — | — | — |
Q4 2025 | Nov 12, 2025 | $-0.24 | $-0.08 | +66.7% | ✓ BEAT |
Q3 2025 | Aug 14, 2025 | $-0.29 | $-0.40 | -37.9% | ✗ MISS |
Q2 2025 | May 13, 2025 | $-0.38 | $-0.37 | +2.6% | ✓ BEAT |
Q1 2025 | Mar 26, 2025 | $-0.39 | $-0.37 | +5.1% | ✓ BEAT |
Q4 2024 | Nov 13, 2024 | $-0.46 | $-0.44 | +4.3% | ✓ BEAT |
Q3 2024 | Aug 12, 2024 | $-0.42 | $-0.52 | -23.8% | ✗ MISS |
Q2 2024 | May 13, 2024 | $-0.57 | $-0.51 | +10.5% | ✓ BEAT |
Q1 2024 | Mar 18, 2024 | $-0.56 | $-0.46 | +17.9% | ✓ BEAT |
Q4 2023 | Nov 13, 2023 | $-0.48 | $-0.51 | -6.3% | ✗ MISS |
Q3 2023 | Aug 14, 2023 | $-0.98 | $-0.91 | +7.1% | ✓ BEAT |
Q2 2023 | May 15, 2023 | $-0.90 | $-3.20 | -255.6% | ✗ MISS |
Q1 2023 | Mar 24, 2023 | $-0.90 | $-1.10 | -22.2% | ✗ MISS |
Q4 2022 | Nov 14, 2022 | $-1.10 | $-1.30 | -18.2% | ✗ MISS |
Q3 2022 | Aug 12, 2022 | $-1.00 | $-1.50 | -50.0% | ✗ MISS |
Q2 2022 | May 13, 2022 | $-1.10 | $-0.90 | +18.2% | ✓ BEAT |
Q1 2022 | Mar 11, 2022 | $-1.10 | $-1.00 | +9.1% | ✓ BEAT |
Q4 2021 | Nov 12, 2021 | $-1.10 | $-1.40 | -27.3% | ✗ MISS |
Q3 2021 | Aug 13, 2021 | $-1.30 | $-1.20 | +7.7% | ✓ BEAT |
Q2 2021 | May 14, 2021 | $-1.10 | $-1.20 | -9.1% | ✗ MISS |
Latest News
Leap Therapeutics Shares Halted On Circuit Breaker To The Upside, Stock Now Up 345.71%
📈 PositiveBenzinga•Nov 12, 2025, 05:56 PM
Leap Therapeutics Shares Halted On Circuit Breaker To The Upside, Stock Now Up 320.57%
📈 PositiveBenzinga•Nov 12, 2025, 05:24 PM
Leap Therapeutics Shares Resume Trade
➖ NeutralBenzinga•Nov 12, 2025, 03:52 PM
Leap Therapeutics shares are trading higher after the company reported better-than-expected Q3 EPS results.
📈 PositiveBenzinga•Nov 12, 2025, 02:18 PM
Leap Therapeutics Q3 EPS $(0.08) Beats $(0.24) Estimate
📈 PositiveBenzinga•Nov 12, 2025, 01:15 PM
Leap Therapeutics Rebrands As Cypherpunk, Will Trade As CYPH Nov. 13, Buys 203,775 ZEC And Adds Khing Oei As Chair, Will McEvoy As CIO
➖ NeutralBenzinga•Nov 12, 2025, 12:03 PM
Leap Therapeutics Reports Final Results From Part B Of DeFianCe Study, Phase 2 Study Of Sirexatamab, In MSS CRC Patients Who Have Received One Prior Systemic Therapy For Advanced Disease
➖ NeutralBenzinga•Oct 20, 2025, 11:07 AM
Leap Therapeutics Closes Private Placement Led By Winklevoss Capital Raising $58.88M In Cash To Initiate Digital Asset Treasury Strategy.
➖ NeutralBenzinga•Oct 9, 2025, 11:16 AM
Leap Therapeutics shares are trading higher after the company announced it secured a $58.9 million private placement in cash commitments led by Winklevoss Capital.
📈 PositiveBenzinga•Oct 6, 2025, 02:30 PM
Leap Therapeutics secures $58.9M PIPE to launch digital asset strategy; shares up 29%
📈 PositiveSeeking Alpha•Oct 6, 2025, 01:33 PM
Leap Therapeutics Secures $58.9M PIPE Led by Winklevoss Capital For ~95.85M Shares And Warrants To Buy ~71.9M Shares
📈 PositiveBenzinga•Oct 6, 2025, 01:05 PM
Leap Therapeutics Slashes R&D Spending
📉 NegativeThe Motley Fool•Aug 14, 2025, 11:23 AM
Frequently Asked Questions about LPTX
What is LPTX's current stock price?
Leap Therapeutics, Inc. (LPTX) is currently trading at $1.09 per share. The stock has moved +16.57% today.
What is the analyst price target for LPTX?
The average analyst price target for LPTX is $5.50, based on 1 analyst.
What sector is Leap Therapeutics, Inc. in?
Leap Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is LPTX's market cap?
Leap Therapeutics, Inc. has a market capitalization of $0.05 billion, making it a small-cap company.
Does LPTX pay dividends?
No, Leap Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAPLM
Apollomics, Inc.
$16.73
Mkt Cap: $0.0B
ASBP
Aspire Biopharma Holdings, Inc.
$0.10
Mkt Cap: $0.0B
ATHA
Athira Pharma, Inc.
$6.97
Mkt Cap: $0.0B
BCTX
BriaCell Therapeutics Corp.
$8.95
Mkt Cap: $0.0B
CRIS
Curis, Inc.
$1.07
Mkt Cap: $0.0B
CTXR
Citius Pharmaceuticals, Inc.
$1.07
Mkt Cap: $0.0B
DARE
Daré Bioscience, Inc.
$2.09
Mkt Cap: $0.0B
ENTO
Entero Therapeutics, Inc.
$1.98
Mkt Cap: $0.0B
ICU
SeaStar Medical Holding Corporation
$0.24
Mkt Cap: $0.0B
PCSA
Processa Pharmaceuticals, Inc.
$3.78
Mkt Cap: $0.0B
Explore stocks similar to LPTX for comparison